243 related articles for article (PubMed ID: 15780738)
1. A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates.
Li SW; Zhang J; Li YM; Ou SH; Huang GY; He ZQ; Ge SX; Xian YL; Pang SQ; Ng MH; Xia NS
Vaccine; 2005 Apr; 23(22):2893-901. PubMed ID: 15780738
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity and efficacy of a bacterially expressed HEV ORF3 peptide, assessed by experimental infection of primates.
Ma H; Song X; Harrison TJ; Li R; Huang G; Zhang H; Kong W; Wang Y
Arch Virol; 2009; 154(10):1641-8. PubMed ID: 19763777
[TBL] [Abstract][Full Text] [Related]
3. Challenge studies in Rhesus monkeys immunized with candidate hepatitis E vaccines: DNA, DNA-prime-protein-boost and DNA-protein encapsulated in liposomes.
Arankalle VA; Lole KS; Deshmukh TM; Srivastava S; Shaligram US
Vaccine; 2009 Feb; 27(7):1032-9. PubMed ID: 19095027
[TBL] [Abstract][Full Text] [Related]
4. A truncated ORF2 protein contains the most immunogenic site on ORF2: antibody responses to non-vaccine sequences following challenge of vaccinated and non-vaccinated macaques with hepatitis E virus.
Zhou YH; Purcell RH; Emerson SU
Vaccine; 2005 May; 23(24):3157-65. PubMed ID: 15837215
[TBL] [Abstract][Full Text] [Related]
5. [Particulate recombinant hepatitis E virus capsid protein and its antigenicity and immunogenicity].
He ZQ; Zhang J; Li SW; Lin J; Liu RS; Chen YX; Wang YB; Xia NS
Sheng Wu Gong Cheng Xue Bao; 2004 Mar; 20(2):262-8. PubMed ID: 15969119
[TBL] [Abstract][Full Text] [Related]
6. [The immuno-protect study of a hepatitis E virus ORF2 peptide expressed in E. coli].
Ge S; Zhang J; Huang G; Pang S; Zhou K; Xia N
Wei Sheng Wu Xue Bao; 2003 Feb; 43(1):35-42. PubMed ID: 16276869
[TBL] [Abstract][Full Text] [Related]
7. Induction of antibody response against hepatitis E virus (HEV) with recombinant human papillomavirus pseudoviruses expressing truncated HEV capsid proteins in mice.
Renoux VM; Fleury MJ; Bousarghin L; Gaitan J; Sizaret PY; Touzé A; Coursaget P
Vaccine; 2008 Dec; 26(51):6602-7. PubMed ID: 18835319
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity and protective efficacy in rhesus monkeys of a recombinant ORF2 protein from hepatitis E virus genotype 4.
Huang WJ; Zhang HY; Harrison TJ; Lan HY; Huang GY; Wang YC
Arch Virol; 2009; 154(3):481-8. PubMed ID: 19240977
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis E vaccine candidate harboring a non-particulate immunogen of E2 fused with CRM197 fragment A.
Wang K; Zhou L; Zhang X; Song C; Chen T; Li J; Zheng M; Wang Y; Zheng Q; Zheng Z; Yu H; Wu T; Gu Y; Zhang J; Zhao Q; Li S; Xia N
Antiviral Res; 2019 Apr; 164():154-161. PubMed ID: 30802475
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of candidate hepatitis E virus DNA vaccine expressing complete and truncated ORF2 in mice.
Deshmukh TM; Lole KS; Tripathy AS; Arankalle VA
Vaccine; 2007 May; 25(22):4350-60. PubMed ID: 17459540
[TBL] [Abstract][Full Text] [Related]
11. Difference of T cell and B cell activation in two homologous proteins with similar antigenicity but great distinct immunogenicity.
Wu T; Wu XL; Ou SH; Lin CX; Cheng T; Li SW; Ng MH; Zhang J; Xia NS
Mol Immunol; 2007 May; 44(12):3261-6. PubMed ID: 17408743
[TBL] [Abstract][Full Text] [Related]
12. [Vaccination of rhesus monkeys with recombinant antigen fragments and protection from hepatitis E virus infection].
Ma YB; Xie TH; Zhang GM; Li CH; Dai XJ; Dai CB; Sun MS; Lu J; Bi SL
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2002 Dec; 24(6):592-5. PubMed ID: 12905686
[TBL] [Abstract][Full Text] [Related]
13. Protective efficacy of hepatitis E virus DNA vaccine administered by gene gun in the cynomolgus macaque model of infection.
Kamili S; Spelbring J; Carson D; Krawczynski K
J Infect Dis; 2004 Jan; 189(2):258-64. PubMed ID: 14722891
[TBL] [Abstract][Full Text] [Related]
14. Cross-protection of hepatitis E virus genotypes 1 and 4 in rhesus macaques.
Huang W; Zhang H; Harrison TJ; Lang S; Huang G; Wang Y
J Med Virol; 2008 May; 80(5):824-32. PubMed ID: 18360896
[TBL] [Abstract][Full Text] [Related]
15. Analysis of hepatitis E virus neutralization sites using monoclonal antibodies directed against a virus capsid protein.
Zhang J; Gu Y; Ge SX; Li SW; He ZQ; Huang GY; Zhuang H; Ng MH; Xia NS
Vaccine; 2005 Apr; 23(22):2881-92. PubMed ID: 15780737
[TBL] [Abstract][Full Text] [Related]
16. The first experimental study on a candidate combined vaccine against hepatitis A and hepatitis E.
Dong C; Dai X; Meng JH
Vaccine; 2007 Feb; 25(9):1662-8. PubMed ID: 17156900
[TBL] [Abstract][Full Text] [Related]
17. Development of candidate combination vaccine for hepatitis E and hepatitis B: a liposome encapsulation approach.
Shrivastava S; Lole KS; Tripathy AS; Shaligram US; Arankalle VA
Vaccine; 2009 Nov; 27(47):6582-8. PubMed ID: 19747579
[TBL] [Abstract][Full Text] [Related]
18. Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.
Zhang M; Emerson SU; Nguyen H; Engle R; Govindarajan S; Blackwelder WC; Gerin J; Purcell RH
Vaccine; 2002 Sep; 20(27-28):3285-91. PubMed ID: 12213398
[TBL] [Abstract][Full Text] [Related]
19. Challenges in creating a vaccine to prevent hepatitis E.
Maloney BJ; Takeda N; Suzaki Y; Ami Y; Li TC; Miyamura T; Arntzen CJ; Mason HS
Vaccine; 2005 Mar; 23(15):1870-4. PubMed ID: 15734058
[TBL] [Abstract][Full Text] [Related]
20. [Preliminary evidence that a hepatitis E virus (HEV) ORF2 recombinant protein protects cynomolgus macaques against challenge with wild-type HEV].
Bi S; Lu J; Jiang L; Huang G; Pan H; Jiang Y; Zhang M; Shen X
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2002 Mar; 16(1):31-2. PubMed ID: 11986741
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
